

Title (en)
METHOD FOR TREATING CANCER

Title (de)
KREBSBEHANDLUNGSVERFAHREN

Title (fr)
METHODE DE TRAITEMENT DU CANCER

Publication
EP 1351677 A4 20090819 (EN)

Application
EP 02720788 A 20020111

Priority
• US 0200943 W 20020111
• US 26312701 P 20010119

Abstract (en)
[origin: WO02056755A2] A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula (I) toxicity-reducing agent. The preferred order of administration is the formula (I) compound, followed by the platinum complex, followed by the taxane agent.

IPC 1-7
A61K 31/335; A61K 31/105; A61K 33/24; A61K 31/663; A61K 31/185; A61P 35/00

IPC 8 full level
A61K 31/185 (2006.01); **A61K 31/282** (2006.01); **A61K 31/337** (2006.01); **A61K 31/555** (2006.01); **A61K 31/663** (2006.01); **A61K 33/243** (2019.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 39/02** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)
A61K 31/185 (2013.01 - EP); **A61K 31/337** (2013.01 - EP); **A61K 31/555** (2013.01 - EP); **A61K 31/663** (2013.01 - EP); **A61K 33/243** (2018.12 - EP US); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 39/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)
• [DA] US 5919816 A 19990706 - HAUSHEER FREDERICK H [US], et al
• [A] WO 9811898 A1 19980326 - BIONUMERIK PHARMACEUTICALS INC [US], et al
• [X] SCHWARTZ GN, SCHILSKY RL ET AL: "Phase I Trial of Escalating Doses of BNP7787 in Patients Receiving Paclitaxel (TAX) and Cisplatin (CDDP)", PROC AM SOC CLIN ONCOL, vol. 19, 2000, pages 218A, XP002534844, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=100040> [retrieved on 20090701]
• [X] SCHILSKY R, SCHWARTZ G ET AL: "Phase I Trial of Escalating Doses of BNP7787 in Patients Receiving Cisplatin (CDDP) and Paclitaxel (TAX)", ASCO ANNUAL MEETING, 1999, XP002534845, Retrieved from the Internet <URL:http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=17&abstractID=14900> [retrieved on 20090701]
• [Y] CAVALLETTI E ET AL: "Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 398, XP001537150, ISSN: 0197-016X
• [Y] HAUSHEER FREDERICK H ET AL: "BNP7787: A novel chemoprotecting agent for platinum and taxane toxicity", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 769 - 770, XP001537151, ISSN: 0197-016X
• [Y] HAUSHEER F ET AL: "BNP7787: A novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 38, 1 March 1997 (1997-03-01), pages 311, XP002052163, ISSN: 0197-016X
• [A] DORR R T: "A REVIEW OF THE MODULATION OF CISPLATIN TOXICITIES BY CHEMOPROTECTANTS", CANCER CHEMOTHERAPY REPORTS, XX, XX, 1 January 1995 (1995-01-01), pages 131 - 154, XP000885450
• [A] ZANETTA G ET AL: "Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer", ANNALS OF ONCOLOGY 199809 NL, vol. 9, no. 9, September 1998 (1998-09-01), pages 977 - 980, XP002534846, ISSN: 0923-7534
• [A] BOISDRON-CELLE MICHELE ET AL: "Platinum compounds-taxanes pharmacologic interactions", BULLETIN DU CANCER, EDITIONS SCIENTIFIQUES ELSEVIER, PARIS, FR, vol. 87, no. numero special, 1 August 2000 (2000-08-01), pages 30 - 33, XP009119107, ISSN: 0007-4551
• See references of WO 02056755A2

Citation (examination)
• CHABNER, B.A. AND LONGO, D.L.: "Cancer Chemotherapy and Biotherapy- Principles and Practice, Second Edition", 1996, LIPPINCOTT-RAVEN PUBLISHING, pages: 285
• ROWINSKY ERIC K ET AL: "Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 119, no. 12, 1993, pages 727 - 733, ISSN: 0171-5216
• PARKER R J ET AL: "Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.", JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS 1993 LNKD- PUBMED:7912534, no. 15, 1993, pages 83 - 88, ISSN: 1052-6773
• ZAFFARONI N ET AL: "Induction of apoptosis by taxol and cisplatin and effect on cell-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells", BRITISH JOURNAL OF CANCER, vol. 77, no. 9, May 1998 (1998-05-01), pages 1378 - 1385, ISSN: 0007-0920
• LIEBMANN J E ET AL: "Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.", ONCOLOGY RESEARCH 1994 LNKD- PUBMED:7919549, vol. 6, no. 1, 1994, pages 25 - 31, ISSN: 0965-0407
• JEKUNEN A P ET AL: "Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro", BRITISH JOURNAL OF CANCER, vol. 69, no. 2, 1994, pages 299 - 306, ISSN: 0007-0920

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 02056755 A2 20020725; WO 02056755 A3 20020926; AU 2002251763 B2 20060504; CA 2434270 A1 20020725; EP 1351677 A2 20031015; EP 1351677 A4 20090819; JP 2004523518 A 20040805; JP 2009292837 A 20091217; MX PA03006359 A 20040420

DOCDB simple family (application)

US 0200943 W 20020111; AU 2002251763 A 20020111; CA 2434270 A 20020111; EP 02720788 A 20020111; JP 2002557269 A 20020111;
JP 2009212441 A 20090914; MX PA03006359 A 20020111